X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR), focused on rare immune system diseases, announced its participation in the Stifel 2024 Healthcare Conference in New York. The company will engage in a fireside chat on Monday, November 18, 2024, at 4:10 PM ET at the Lotte New York Palace. A live webcast will be available through X4's website's investor section, with a replay accessible after the event. The company will also be available for one-on-one meetings with investors, which can be arranged through Stifel representatives.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
On the day this news was published, XFOR gained 47.85%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.
| Stifel 2024 Healthcare Conference | |
| Date: | Monday, November 18, 2024 |
| Time: | 4:10PM ET |
| Format: | Fireside Chat |
| Location: | Lotte New York Palace, New York |
| Webcast Link | |
A link for this live webcast will also be accessible through the “events & presentations” page in the investors section of X4 Pharmaceuticals’ website. After the conclusion of the conference, a webcast replay will be available through the same link.
The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Stifel representative to request meetings.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When is X4 Pharmaceuticals (XFOR) presenting at the Stifel 2024 Healthcare Conference?
Where can investors watch X4 Pharmaceuticals' (XFOR) Stifel Conference presentation?
How can investors schedule one-on-one meetings with X4 Pharmaceuticals (XFOR) at the Stifel Conference?
Where is the Stifel 2024 Healthcare Conference being held for X4 Pharmaceuticals (XFOR)?
